Using Electric Fields to Treat Tumors: Combining Standard and Innovative Treatments

Using Electricity to Treat Tumors: Standard and Innovative Treatments

Mesothelioma is a rare cancer and standard therapies are limited. So most patients consider one or more different treatments. Different types of therapies can be used and they are usually not exclusive. Mesothelioma patients can move from one type to another. And, if their doctors agree, can sometimes use them in combination. One of the non-standard treatment therapies is the use of electric fields. Tumor-treating electric fields can disrupt cancer cell division. This treatment is approved for mesothelioma treatment. A new combination of treatments has recently been proposed. Does the combination of tumor-treating fields with a standard treatment effective? A new global clinical trial combined tumor-treating fields with sorafenib. This medication blocks cell protein signals to prevent cancer cells from … Continue reading Using Electric Fields to Treat Tumors: Combining Standard and Innovative Treatments »

Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab

Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab

Canadian researchers say radiotherapy may hold the key to improving outcomes in mesothelioma. Mesothelioma is a fast-growing membrane cancer caused by asbestos. Doctors have not found a single therapy that can beat it. For most patients, a combination of treatments offer the best survival odds. Pembrolizumab plus Radiotherapy Pleural mesothelioma is a rare lung-related cancer caused by asbestos exposure. There is no cure for mesothelioma. Most mesothelioma patients have a combination of therapies. Radiation is one of the methods doctors use to help slow its spread. Outcomes in mesothelioma vary widely with the use of radiotherapy. Pembrolizumab is used in combination with chemotherapy as a first-line treatment for mesothelioma. Radiotherapy uses beams of intense energy to kill cancer cells. One … Continue reading Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab »

Radiation Therapy for Mesothelioma Patients: Value and Timing

Radiation Therapy for Mesothelioma Patients: Value and Timing

The value and safety of radiation therapy for mesothelioma patients are promising. Oncologists from the Fox Chase Cancer Center released new data on radiotherapy. What are the options for radiation therapy? What is the best timing? Who should receive it? This guide shows the role of radiotherapy in the treatment of mesothelioma. Mesothelioma Radiosensitivity and Treatment Combinations Mesothelioma tumors are radiosensitive. This means they are sensitive to X-rays and radiant energy forms. In other words, mesothelioma tumors are treatable with radiation therapy. The use of a multi-modality treatment has also shown potential for mesothelioma patients. A tri-modality treatment uses three different treatment types. The combination of surgery, chemotherapy, and radiotherapy is most common. Understanding Timing and Adverse Effects There are … Continue reading Radiation Therapy for Mesothelioma Patients: Value and Timing »

Nivolumab + Ipilimumab Provides Long-Term Survival Benefit in Malignant Pleural Mesothelioma

Nivolumab + Ipilimumab Provides Long-Term Survival Benefit

Nivolumab + ipilimumab continues to provide a long-term survival benefit in malignant pleural mesothelioma. A new report shows a 3-year follow-up in the CheckMate Clinical Trial. Long-term clinical benefits remained the same for all patient groups. Background on the Nivolumab + Ipilimumab Treatment Two years ago, the FDA approved the combination of nivolumab + ipilimumab. It is the first-line treatment for patients with metastatic non-small cell lung cancer. The CHECKMATE randomized multi-part trial investigated the effectiveness. The trial showed a significant improvement in patient survival. Today, this treatment combination improves patient survival rates over chemotherapy. Mesothelioma patients showed an improved survival using this line of treatment. A new report from the Annals of Oncology describes updated data with at least … Continue reading Nivolumab + Ipilimumab Provides Long-Term Survival Benefit in Malignant Pleural Mesothelioma »

Mesothelioma Patients with Coronavirus: Artificial Intelligence to Provide Best Treatment Plan

Mesothelioma Patients with Coronavirus and Artificial Intelligence

Mesothelioma patients are vulnerable to the coronavirus due to their poor immune response. Artificial intelligence can provide information used to treat cancer patients diagnosed with coronavirus. Hospitals have access to real-time data from cancer patients. Artificial intelligence uses this data to predict the severity of the patient’s risk. And, it can help physicians alter or change their treatment plans. A mix of treatment therapies can heal mesothelioma patients with coronavirus. Artificial intelligence can predict a patient’s treatment plan to increase survival rates. Coronavirus Disrupts Normal Treatment Plans The coronavirus pandemic has caused chaos throughout the world. The key threat of the coronavirus is in immune-compromised mesothelioma patients. Their weakened immune response makes them weak and at risk. Oncologists and their … Continue reading Mesothelioma Patients with Coronavirus: Artificial Intelligence to Provide Best Treatment Plan »

A Multimodality Treatment Plan may be Best for Pleural Mesothelioma

A Multimodality Treatment Plan may be Best for Pleural Mesothelioma

A multimodality treatment plan may improve mesothelioma patient outcomes. Malignant pleural mesothelioma is an invasive, locally aggressive tumor related to asbestos exposure. A new study shows that the best treatment plan for pleural mesothelioma may be when different types of therapy work together. The ideal combination of treatment therapies is still unknown. But a recent study encourages further studies on a multimodality treatment plan. This may include chemotherapy, surgery, and adjuvant radiotherapy. Current Clinical Guidelines: A History of Single or Multimodality Treatment Plans Despite a long history of clinical research, there is still no cure or any evidence of the best treatment. Many single-treatment plans, single-modality plans, have had disappointing results. Researchers have begun to evaluate different multi-modal treatment approaches. … Continue reading A Multimodality Treatment Plan may be Best for Pleural Mesothelioma »

Treatment Options Improving in the ‘New Era’ for Mesothelioma

treatment options

Calling it a “new era” for malignant pleural mesothelioma, doctors from four of the nation’s top cancer centers have just published an update on treatment options for this rare disease.  The article was prepared by mesothelioma experts at MD Anderson Cancer Center in Texas, NYU Langone Medical Center, Memorial Sloan Kettering Cancer Center in New York and the Mayo Clinic in Minnesota.  The article in the Journal of Clinical Oncology highlights the recent FDA approvals of a new medical device and a new immunotherapy combination for pleural mesothelioma. The authors say these and other advances are “generating momentum” to find better mesothelioma therapies.  Tumor Treating Fields Changing the Game Pleural mesothelioma is fast-growing and difficult to treat. Mesothelioma rarely responds … Continue reading Treatment Options Improving in the ‘New Era’ for Mesothelioma »

Surgery-Based Multimodal Treatment Improves Survival for Italian Mesothelioma Patients

surgery-based multimodal treatment

A new Italian report suggests that a surgery-based multimodal treatment approach to mesothelioma can help patients live longer with few serious side effects.  The new study comes from Careggi University Hospital in Florence. Thoracic oncologists tracked the outcomes of 12 of their mesothelioma patients since 2017. All of the patients had early-stage pleural mesothelioma of the epithelioid subtype. Results showed that none of them died within the first year after surgery-based multimodal treatment. More than half lived for at least three years.  These are considered very positive results for a cancer that often claims lives within months of diagnosis.  Understanding Surgery-Based Multimodal Treatment Some types of cancer can be successfully treated with just one type of therapy. Pleural mesothelioma is … Continue reading Surgery-Based Multimodal Treatment Improves Survival for Italian Mesothelioma Patients »

New Mesothelioma Trial to Test Tri-Modal Approach

new mesothelioma trial

Enrollment is open for a new mesothelioma trial run by Memorial Sloan Kettering Cancer Center to test a three-prong approach to treatment.  Pleural mesothelioma is a lung-related cancer caused by asbestos. It is notoriously difficult to treat and highly aggressive.  The new mesothelioma trial aims to recruit 150 pleural mesothelioma patients. Patients will receive lung-sparing surgery and chemotherapy. Some will also receive intensity modulated radiation therapy (IMRT).  Researchers will test which group does better – those who only have surgery and chemotherapy or those who also have targeted radiation therapy. They plan to measure not only survival but also complications, quality of life, and how long it takes for the cancer to come back.  Tri-Modal Treatment to Fight Mesothelioma The … Continue reading New Mesothelioma Trial to Test Tri-Modal Approach »

Access to Multi-Modality Mesothelioma Treatment Limited for Uninsured & Rural Residents

access to multi-modality mesothelioma treatment

A new study shows a person’s insurance status and where they live often impact their access to multi-modality mesothelioma treatment. This can have an impact on their survival.  Researchers at the University of Miami Sylvester Comprehensive Cancer Center conducted the new study. They shared their findings at the recent virtual world conference of the International Association for the Study of Lung Cancer.  The study found that access to multi-modality mesothelioma treatment was more common in patients with private insurance or Medicare. It was also more common among those who lived closer to larger medical centers.  People who lived further out or who did not have insurance often did not receive the treatments that offer the best odds of mesothelioma survival. … Continue reading Access to Multi-Modality Mesothelioma Treatment Limited for Uninsured & Rural Residents »

Get your free copy of
“Surviving Mesothelioma” Today!